Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis for zebrafish tumors driven by overexpression of human IRF4

ABSTRACT: RNA-seq analysis for zebrafish tumors driven by overexpression of human IRF4

PROVIDER: PRJNA578840 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10322136.fastq.gz	Fastqsanger.gz
	SRR10322137.fastq.gz	Fastqsanger.gz
	SRR10322138.fastq.gz	Fastqsanger.gz
	SRR10322139.fastq.gz	Fastqsanger.gz
	SRR10322140.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Zebrafish tumors driven by overexpression of human IRF4

Project description:Zebrafish tumors driven by overexpression of human IRF4

| PRJNA701471 | ENA

RNA-seq analysis for zebrafish tumors driven by overexpression of human IRF4

Project description:RNA-seq analysis was performed using zebrafish primary tumors and control thymus to analyze gene expression changes after IRF4 overexpression.

2022-03-14 | GSE139226 | GEO

H3K27ac ChIP-seq analysis for zebrafish normal thymus and tumors driven by overexpression of human IRF4

Project description:H3K27ac ChIP-seq analysis was performed using zebrafish normal thymus and primary tumors to analyze potential regulatory elements activated by IRF4 overexpression.

2022-03-14 | GSE166644 | GEO

H3K27ac ChIP-seq analysis for zebrafish normal thymus and tumors driven by overexpression of human IRF4

Project description:H3K27ac ChIP-seq analysis for zebrafish normal thymus and tumors driven by overexpression of human IRF4

| PRJNA701468 | ENA

RNA-seq analysis for IRF4-driven zebrafish tumors after JQ1 treatment

Project description:RNA-seq analysis for IRF4-driven zebrafish tumors after JQ1 treatment

| PRJNA767083 | ENA

Single cell RNA-seq analysis for normal lymphocytes and IRF4-driven zebrafish tumors

Project description:Single cell RNA-seq analysis for normal lymphocytes and IRF4-driven zebrafish tumors

| PRJNA701473 | ENA

RNA-seq analysis for IRF4-driven zebrafish tumors after JQ1 treatment

Project description:RNA-seq analysis was performed using tumor cells driven by IRF4 to analyze gene expression changes after JQ1 treatment

2022-03-14 | GSE184946 | GEO

Single cell RNA-seq analysis for normal lymphocytes and IRF4-driven zebrafish tumors

Project description:Single cell RNA-seq analysis was carried out for 1 normal sample from a control zebrafish line (lck-mCherry) and 5 non-tumor and 14 tumor samples from the IRF4 transgenic line (lck-IRF4). Tumor cells were harvested from the animals with or without heterozygous p53 mutation at different time points of tumor development.

2022-03-14 | GSE166646 | GEO

Zebrafish tumors driven by overexpression of human IRF4

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-03-14 | GSE166650 | GEO

Targeting superenhancer-driven PRKCN mediated mTOR-IRF4 signaling as a potential strategy against multiple myeloma

Project description:Multiple myeloma (MM) remains incurable, necessitating development of novel therapeutic targets. Deregulated PRKCN contributes to development of solid tumors, while its role in MM remains elusive. In present, we identified PRKCN as a superenhancer-driven gene abundantly expressed in MM. PRKCN was transactivated by NF-κB signaling intrinsically existing or exogenously provoked, nominating PRKCN as a novel NF-κB target gene. Constitutive or inducible knockdown of PRKCN significantly impaired cell growth and tumorigenicity, while overcoming drug resistance and triggering apoptosis. The growth-inhibition elicited by PRKCN depletion was considerably rescued by IRF4 overexpression, supporting PRKCN functioned through IRF4. Intriguingly, IRF4 reciprocally transactivated PRKCN, thereby forming a positive feedback loop. Furthermore, PRKCN favored IRF4 expression by activating mTORC1/C2 signaling, which was associated with direct and extensive interaction with mTOR. Unexpectedly, although PRKCN could directly phosphorylate mTOR in vitro, it modulated mTOR-IRF4 axis and MM cell growth independently of intrinsic kinase activity yet requiring phosphorylation of activation loop. Noteworthily, targeting PRKCN with an orally bioavailable inhibitor suppressed the growth of cell lines together with primary samples and overcame drug resistance in vitro, and also elicited robust efficacy in a cell line-derived xenograft and a patient-derived xenograft, which was connected with mitigated activation loop phosphorylation of PRKCN and mTOR-IRF4 axis. Collectively, our study delineates PRKCN function that links NF-κB signaling and mTOR-IRF4 axis orchestrating cell growth and survival, providing the proof-of-concept for potentially targeting PRKCN to antagonize MM.

2025-08-13 | GSE305283 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data